SPY003 Hits Primary Endpoint in Phase 2 SKYLINE Trial, Completing Proof-of-Concept for All Three IBD Components
SYRE has more than doubled off its 52-week low of $14.505.
Summary
Positive Phase 2 SKYLINE Part A data for SPY003 in ulcerative colitis were announced by Spyre Therapeutics, meeting its primary endpoint with a 10.0-point RHI reduction (p<0.0001). The result completes proof-of-concept for all three components of its IBD combination strategy.
Key Events · Product Development and Regulatory · SYRE
-
SPY003 Meets Primary Endpoint
At Week 12 in the Phase 2 SKYLINE Part A trial for ulcerative colitis, SPY003 achieved a statistically significant 10.0-point reduction in RHI score (p<0.0001).
-
Clinical Remission and Endoscopic Improvement
SPY003 demonstrated a 20% clinical remission rate and 30% endoscopic improvement rate, with a -3.5 change in modified Mayo Score.
-
Safety Profile Consistent with IL-23 Class
SPY003 was well tolerated: 19 subjects (43%) had TEAEs, 3 SAEs (7%) were deemed not drug-related, and there were no drug-related SAEs, no discontinuations due to AEs, and no deaths.
-
POC Complete for All Three IBD Components
With SPY003 data, Spyre has now reported positive Part A results for SPY001 (anti-α4β7), SPY002 (anti-TL1A), and SPY003 (anti-IL-23) — all three mechanisms in its IBD portfolio — validating the combination strategy.
Analysis · SYRE · Life Sciences
Positive 12-week induction data for SPY003, Spyre Therapeutics' anti-IL-23 candidate for ulcerative colitis, were reported today. The drug achieved a statistically significant 10.0-point reduction in RHI score (p<0.0001), along with a 20% clinical remission rate and 30% endoscopic improvement rate. This result completes clinical proof-of-concept for all three monotherapies in Spyre's IBD portfolio — SPY001 (anti-α4β7), SPY002 (anti-TL1A), and SPY003 (anti-IL-23) — validating the biological rationale for the combination strategy being tested in Part B of the SKYLINE trial. The safety profile was consistent with the IL-23 class, with no drug-related serious adverse events. This is the third positive IBD readout in five months, strengthening the company's position ahead of the SKYWAY readout for SPY072 in 4Q 2026 and the SKYLINE Part B combination data expected in 2027.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 35.7% of the 1694 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.10%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SYRE was trading at $88.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.8B. The 52-week trading range was $14.51 to $110.18. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.